# Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

Source: https://onco.cc/trials/nct04836507/  
OnCo record `nct04836507` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CRC01, Fludarabine, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Curocell Inc., now recruiting.

## Summary

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients is a phase 1/2 interventional study registered as NCT04836507 by Curocell Inc., with 91 participants planned, started 2021-03-02 and due to reach its primary completion in 2030-08-15. Interventions recorded: CRC01, Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04836507
- Phase: 1/2
- Setting: An Open-label, Multi-center, Single-arm Phase 1/2 Study to Assess Tolerability, Safety and Efficacy of CRC01 in Adult Patients With Relapsed or Refractory Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
- Sponsor: Curocell Inc.
- Enrolled: 91

## Sources

- ClinicalTrials.gov NCT04836507: https://clinicaltrials.gov/study/NCT04836507

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [CRC01](https://onco.cc/drugs/crc01/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct04836507.json